Aurobindo Pharma gets USFDA nod for Levofloxacin injection
Advertisement
New Delhi: Aurobindo Pharma said it has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Levofloxacin injection, an anti-infective used in the treatment of bacterial infection in adults.
The approval is for Levofloxacin in 5 per cent Dextrose injection in the strengths of 250 mg/50 ml, 500 mg/100 ml, and 750 mg/150 ml, single use containers, Aurobindo Pharma said in a BSE filing.
The approval is for Levofloxacin in 5 per cent Dextrose injection in the strengths of 250 mg/50 ml, 500 mg/100 ml, and 750 mg/150 ml, single use containers, Aurobindo Pharma said in a BSE filing.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.